All News

On this episode of Managed Care Cast, we address how delays in routine care and other aspects of the pandemic are affecting payer organizations today, and how technology innovations like natural language processing can work to empower key initiatives in population health and beyond.

The Supreme Court announces it will hear arguments for Mississippi’s case to overturn the landmark Roe v Wade decision on December 1; the Biden administration aims to address extreme heat conditions in the workplace; rehab timing may affect stroke recovery.

An updated report shows that the long-term cost of treating the health effects of polycystic ovary syndrome (PCOS)—$4.3 billion—is even higher than $3.7 billion it takes to diagnose and treat immediate issues that present for women who are of reproductive age.

Results of a longitudinal study outline the relationship between depression and patients reported outcomes among those with chronic obstructive pulmonary disease (COPD).

Incidence and risk of myopia development were found to rise significantly among young Chinese schoolchildren who were exposed to environmental changes caused by COVID-19 between grades 2 to 3.

Byooviz becomes the first FDA-approved ophthalmology biosimilar and the first FDA-approved biosimilar referencing Lucentis (ranibizumab), according to a statement from developers Samsung Bioepis and Biogen.

New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.

Pfizer says a newly formulated dose of its vaccine is safe and effective in children; CDC data underscore the efficacy of the 3 COVID-19 vaccines; Biden aims to reform health care with trillion-dollar package.

Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.

A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL).

Unlike the success seen in other cancer types, biomarker-driven treatment advances in gastroesophageal adenocarcinoma (GEA) have been hindered by its genomic heterogeneity. A significant proportion of patients also develop resistant subclones through selective pressure, resulting in disease progression.

Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, details the ways that the treatment of eosinophilic asthma differs from other forms of asthma.

Patients who are treated with direct-acting antivirals to treat hepatitis C virus (HCV) are still at risk of developing hepatocellular carcinoma (HCC).

A new report shows patient readmissions and mortality dropped among patients aged 65 and older following the institution of an antibiotic stewardship program.

The prespecified analysis of DESTINY-Breast03 opened a Presidential Symposium September 18, during the European Society of Medical Oncology (ESMO) 2021 Virtual Congress, with the study’s lead author predicting a new standard of care and a commentator calling the results “startling.”

Considering the personal, societal, and economic toll of treatment-resistant depression, we must make it easier to access medicines and care that provide value, both for the patient and for the health care system.

Although some cancers are falling for rural US residents, liver cancer is on the rise, a new study has found.

A systematic review that aimed to find out more about how growth hormone deficiency (GHD) affects children's oral and dental development found that knowledge gaps still remain.

Clinicians are finding that there really is no basis to recommend probiotics for patients with Clostridioides difficile infection, that instead they may cause harm, said Colleen R. Kelly, MD, FACG, gastroenterologist and associate professor of medicine at The Warren Alpert Medical School of Brown University.

Real-world outcomes can differ from those seen in tightly-controlled clinical trials, so researchers wanted to examine the patterns of growth hormone treatment in a large cohort of children in Israel.

The data offer novel insights, as comparable data on the drug class is scarce despite 2 JAK inhibitors being approved for use in myelofibrosis and others showing promise.

Investigators confirmed prognostic biomarkers for premenopausal patients with hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, which could potentially be used to inform treatment decisions.

High-dose trivalent flu vaccine was associated with a reduced risk of hospitalization and emergency department visits for pneumonia or influenza in adults aged 65 and above, according to a recent study.

A new analysis of 2014-2018 data among all states plus Washington, DC, for those who have either indications for preexposure prophylaxis (PrEP) or current prescriptions for the preventive treatment, shows a widening gap in PrEP uptake, with states considered early adopters pulling ahead of those considered late adopters.

Treatment of guselkumab was found to be safe and effective in improving health-related quality-of-life (HRQOL) and skin manifestations of patients with moderate to severe psoriasis in a real-world setting.

In May, results showed that cemiplimab (Libtayo, Regeneron/Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression.

On top of a general rise in chronic obstructive pulmonary disease (COPD) rates, the study found data suggesting increases not tied to a past history of smoking in several occupations.